These results demonstrate that STOML2 promotes cell proliferation and aerobic glycolysis in MM through regulation of PAI-1 expression, providing a new mechanism of MM progression and a novel therapeutic target for drug discovery. Here, STOML2 is linked to Miyoshi myopathy.